Full Press Release Details
2 2 Notice Regarding Forward-Looking Statements This presentation contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets,
projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms,"
"intends," "anticipates," "plans," "projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by
AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of
AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions
by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain
challenges including the cost and availability of raw materials), the results of ongoing litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of
product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market
acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate
acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024. AngioDynamics does not assume any obligation
to publicly update or revise any forward-looking statements for any reason.
3 Edit Title 3 Pursue Larger, Faster Growing Markets Significantly expanded the
scope of our Med Tech portfolio through R&D, M&A, and clinical/regulatory initiatives by entering the mechanical thrombectomy market, capitalizing on the solid PAD market, and building on the under-penetrated prostate focal therapy
market. Drive Portfolio Transformation Exited and/or divested certain non-strategic businesses, reallocating resources into differentiated technologies, an expanded and robust R&D pipeline, and investing in clinical data generation while
exploring new indications to drive growth opportunities. Improve Financial Profile and Capital Structure Through strategic business development efforts, we recapitalized our balance sheet and transformed our portfolio to drive future margin
expansion and sustained profitable growth. $3 B $10 B FY 2021 FY 2024 Med Tech Global TAM +233%
4 4 Peripheral Artery Disease (PAD) $760M US TAM Venous Thromboembolism
(VTE) $5.3B US TAM Prostate Care $2.7B Global TAM ($780M US) A leading medical technology company driving sustained growth and profitability through its commitment to expanding treatment options, enhancing patient outcomes, and improving
quality of life, with a strategic focus on combating cardiovascular disease and cancer.
5 To Become An innovative, versatile, hour-long prostate
treatment *1,2 *Treatment time does not include patient prep, anesthesia initiation or recovery room time. 1-2 See reference page
6 The First Non-Thermal, Radiation Free Ablation Technology The only FDA cleared
technology that uses electricity to destroy prostate tissue Robust IP Portfolio Clinical Outcomes Patients and Physicians Need Over 2,600 patients have been treated under protocol with 32 peer-reviewed studies The only technology with an
Ablate and Resect Trial 3 Building Momentum and Strong Commercial Viability FDA clearance and CE Mark Approval for prostate tissue IRE CPT 1 codes for prostate and liver approved 9/2024 and effective 01/2026 Proven Go-To Market Strategy For
Developing New Markets Comprehensive clinical support, physician education, and patient awareness initiatives Combined with one of the largest dedicated sales and clinical teams within our market 3 - See reference page REV 01 GL/ON/PR/3126
7 *The NanoKnife System indications for use vary per region. Please refer to the
indications for use for approved use per region
The most diagnosed male cancer in 112 countries, including the U.S.4 annual
diagnoses in the U.S. annual diagnoses 5 worldwide Incidence projected to double by 20404 The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions. -The Lancet Commission on
Prostate Cancer: Planning for the Surge in Cases Aging populations Increasing life expectancy Takes more healthy years from men's lives than any other cancer 6 4-6 See reference page 8 REV 01 GL/ON/PR/3126
Radical surgery or external beam radiation therapy 8 REV 01
GL/ON/PR/3126 7 8 9 7-9 See reference page AngioDynamics Internal Estimates
Active Surveillance Possibility of cancer progression Definitive Treatment Risk
of serious long term urological side effects 5 years 50.2% 10 years 38.7% 15 years 33.7% Erectile Dysfunction Urinary Incontinence Baseline 34% 1-year 85% Erectile Dysfunction Urinary Incontinence Baseline 30% 1-year 71% Baseline
32% 1-year 62% Baseline 31% 1-year 39% Between Their Quality of Life or Controlling Their Cancer Low Risk Intermediate Risk High Risk Neoadjuvant ADT 30.2% 48.5% 79.1% Treatment Failure* 9.7% 22.7% 42.9% *at 8-year
follow-up Of patients will avoid treatment, but this group will have more clinical progression, metastases, and androgen-deprivation therapy initiation when compared with patients who undergo definitive therapy10 11 12 12 13 10-13 See
reference page 10 REV 01 GL/ON/PR/3126
Which aims to destroy the index lesion while preserving the natural anatomy,
continence and erectile function14 Advanced Imaging Patient Selection "Index Lesion" Most lethal metastatic prostate cancers originate from a single cell within the Index Lesion' of the prostate.15 Active Surveillance Definitive
Therapy Focal Therapy Accurate treatment of just the index lesion can control progression or recurrence of the disease.14 10 REV 01 GL/ON/PR/3126 14-15 See reference page
17 18 19 20 21 22 23 24 25 of diagnosed patients undergo a focal
therapy each year 10 REV 01 GL/ON/PR/3126 AngioDynamics Internal Estimates Focal Therapy (7,000) Potential Clinically Appropriate Patients
Learning Curve Time Constraints Reproducible Results Today, focal therapy
options are only ideal for a specific segment of the prostate. A piecemeal approach to focal therapy is prohibitive to broader physician adoption and limits patien ts' access to care. Increased Costs Complex Integration Support &
Staffing Cryo HiFu Brachy ? 10 REV 01 GL/ON/PR/3126 Other Technologies: Transurethral Ultrasound Water Vapor Pressurized Water Nano Particles Microwave Laser
That Can Enable Broad Physician Adoption And Improved Care For
Patients 1 2 3 1,2 10 REV 01 GL/ON/PR/3126 1-3, 16-18 See reference page 1,16 1,3,17,18,19
16 REV 01 GL/ON/PR/3126
Sufficient voltage permanently opens the ion channels of the cell IRE selectively
targets cell membranes20 16 REV 01 GL/ON/PR/3126 20 Cell loses homeostasis leading to cell death20 20 - See reference page
And Aims to Preserve the Nerves, Urethra, and Urinary Sphincters 21,22 21,22 -
See reference page 16 REV 01 GL/ON/PR/3126
In Prostate Tissue Ablation *For detailed information, refer to the FDA's
guidance document titled "Clinical Investigations for Prostate Tissue Ablation Devices." Regulatory Clarity Encourages Innovation Prioritizes Patient Safety The NanoKnife System with six outputs is indicated for surgical ablation of soft
tissue. Indication before PRESERVE Trial International Prostate Data 32 publications 2,642 patients 1 2 *Clinical studies should establish a technologies ability to: 1,2 20 REV 01 GL/ON/PR/3126 1,16 1,3,17,18,19 1-3. 16,19 See
Pivotal study of the NanoKnife System for ablation of prostate tissue in patients
with intermediate-risk prostate cancer 20 REV 01 GL/ON/PR/3126
The PRESERVE Study Experience IRE IRE IRE IRE Avg. Procedure Time 54.1
Minutes Avg. # of Electrodes 4.3 Avg. Procedure Time 54.1 Minutes Avg. # of Electrodes 4.3 Avg. Procedure Time 54.1 Minutes Avg. # of Electrodes 4.3 Mean Procedure Time Mean # of Electrodes 54.1 Minutes 4.3 *Treatment time does
not include patient prep, anesthesia initiation or recovery room time. 1,2 - See reference page Anterior 41.7% Apex 40.8% Posterior 58.3% Base 15.0% Midline 44.2% 20 REV 01 GL/ON/PR/3126 1,2
The Treatment Utilizes Existing Imaging and Biopsy Skills NanoKnife
Electrodes P rostate Bladder Transrectal Ultrasound Probe Grid Subjects Clinical Sites IRE-na ve Sites 121 17 14 The PRESERVE Study Experience 20 REV 01 GL/ON/PR/3126 Gleason 3+4 80.2% Gleason 4+3 19.8% Stepper 1,16 1,16 -
IRE has the lowest impact on sexual function compared to Hifu and Cryo And
provides strong ablation of targeted tissue A 2024 meta-analysis and systematic review of all primary studies reporting outcomes for focal therapy 23 * *All IRE Data Collected Utilizing The NanoKnife System 20 REV 01 GL/ON/PR/3126 23 -
U.S. Experience Confirms Strong International Data 1,16,17,18,19 *Data on file -
Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue (PRESERVE) 20 REV 01 GL/ON/PR/3126
That Can Enable Broad Physician Adoption And Improved Care For
Patients 1 2 3 High level of experience with needle-based procedures Uses existing imaging and biopsy skills Reliable ablations with no skip lesions or heat sink Increased margin expansion without negatively impacting erectile or urinary
function Does not restrict future treatment options 1,2 Not limited by gland size, tumor location, or calcifications Able to ablate across the urethra, nerves, and urinary sphincters Enables physicians to build expertise in a single
technology Typically, an hour procedure* 1,16 *Treatment time does not include patient prep, anesthesia initiation or recovery room time 1-3, 16-19 See reference page 1,3,17,18,19 20 REV 01 GL/ON/PR/3126
Capital Equipment Single-Use Disposable Electrodes (2-6 per procedure) Hardware
Software Accessories Recurring Revenue 28 REV 01 GL/ON/PR/3126
1 Regulatory Approvals Key Market Penetration Tactics *Based on potential
procedures in countries with active NanoKnife users. Market Access Strong Go-To Market Strategy 28 REV 01 GL/ON/PR/3126
The NanoKnife System is indicated for the ablation of prostate tissue in patients
with intermediate risk prostate cancer. The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. 32 publications across 2,642 patients Pivotal Study of the NanoKnife
System 28 REV 01 GL/ON/PR/3126 for the ablation of prostate tissue in patients with Intermediate-Risk Prostate Cancer
US Coverage: US Coding: US Payment: IRE included in the Medicare Fee Schedules
for ASC and Hosp Outpatient settings effective 01/2021 IRE CPT 1 codes for prostate and for liver approved 9/2024 and effective 01/2026 APC 5362 - HOPPS 2025 national average payment $10,411 (+6% yoy) Canada: WIRED Trial: Designed to be a
prospective, non-randomized study in 100 subjects treated at up to 5 clinical sites. 1 North America United Kingdom: Institute for Health and Care Excellence (NICE) upgraded the use of the NanoKnife System to "Special Arrangements" allowing
hospitals to start new services while collecting more data. PART Trial (RCT) comparing the effectiveness of partial prostate ablation vs radical prostatectomy across 800 patients. Sweden: Prostate Cancer IRE Study (PRIS): A randomized
controlled trial comparing focal therapy to radical treatment in localized prostate cancer - evaluating functional and oncological outcomes + an economic evaluation of each technique. Netherlands: ENFORCE Trial - A Dutch government sponsored
and funded RCT that includes the NanoKnife System for prostate treatment. 2 Europe China: Included in the Beijing medical insurance catalog: patients can be reimbursed 85% of the cost of the surgery and electrodes, effective from
10/20/24 3 Asia 28 REV 01 GL/ON/PR/3126
Direct Sales & Partnerships Patient Awareness Physician Education There is
an increasing trend toward using the internet as the first source of health information compared to family/friends/coworkers, health care professionals, and traditional media. -US Health Information National Trends Survey Enhanced Customer
Relationships Improved Product Utilization Market Agility Hands-on Training Master Course and Life Symposium Physician Finder 28 REV 01 GL/ON/PR/3126
33 Internal AngioDynamics Data As of Q2
2024 ASC 20% Private/Public 24% Academic Center 56% Active Sites at the End of Q2 2024 Create a Strong Opportunity for Growth in the Future Physician Acquisition Procedural Adoption Active Facilities Active Physicians Care
Site REV 01 GL/ON/PR/3126
34 Large and growing addressable market Innovative, versatile, ~hour-long
prostate treatment* Addresses an unmet need for physicians, their facility, and their patients Backed by strong clinical evidence Upcoming Category 1 Payment effective 01/2026 Strong revenue model built for growth Commercial team capable
of developing new markets through education *Treatment time does not include patient prep, anesthesia initiation or recovery room time REV 01 GL/ON/PR/3126
Data on file - Pivotal Study of the NanoKnife System for the Ablation of Prostate
Tissue (PRESERVE) Scheltema, Matthijs J et al. "Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments." Diagnostic and interventional radiology (Ankara, Turkey) vol.
24,5(2018): 268-275. doi:10.5152/dir.2018.17374 Van den Bos, W., et al. "Histopathological outcomes after irreversible electroporation for prostate cancer: Results of an ablate and Resect study." Journal of Urology, vol. 196, no. 2, Aug. 2016,
pp. 552-559, https://doi.org/10.1016/j.juro.2016.02.2977. The Lancet Commission on prostate cancer: planning for the surge in cases James, Nicholas D et al. The Lancet, Volume 403, Issue 10437, 1683 - 1722 Cancer in men: Prostate cancer is #1
for 118 countries globally. American Cancer Society. (2024, September 27). https://www.cancer.org/research/acs-research news/prostate-cancer-